Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Integrin alpha L beta 2

Integrin alpha L beta 2

Brief Information

Name:Integrin alpha-L/beta-2 (LFA-1)
Target Synonym:Lymphocyte Function-Associated Antigen-1
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
IT2-H53W3 Human Human Integrin alpha L beta 2 (ITGAL&ITGB2) Heterodimer Protein, His Tag&Tag Free
ACRO Quality

Part of Bioactivity data

 Integrin alpha L beta 2 ELISA

Immobilized Human ITGAL&ITGB2 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT2-H53W3) at 10 μg/mL (100 μL/well) can bind Human ICAM-1, Fc Tag (Cat. No. IC1-H5250) with a linear range of 0.4-6 ng/mL (QC tested).

Synonym Name

Integrin alpha L beta 2,ITGAL&ITGB2


Integrin alpha-L beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. Integrin alpha L beta 2 is also a receptor for F11R (By similarity). Involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes. Contributes to natural killer cell cytotoxicity. Involved in leukocyte adhesion and transmigration of leukocytes including T-cells and neutrophils. Required for generation of common lymphoid progenitor cells in bone marrow, indicating the role in lymphopoiesis. Integrin alpha L beta 2 in association with ICAM3, contributes to apoptotic neutrophil phagocytosis by macrophages.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Lifitegrast SHP-606; SAR-1119; SAR-1118; OJL-332; SPD-606 Approved Shire Development Llc Xiidra United States Dry Eye Syndromes Bausch And Lomb Inc 2016-07-11 Keratoconjunctivitis Sicca; Graft vs Host Disease; Dry Eye Syndromes; Diabetic macular oedema; Conjunctivitis, Allergic; Xerophthalmia Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Alintegimod 7HP349; 7-HP-349; 7HP-349 Phase 2 Clinical 7 Hills Pharma LLC Kidney Neoplasms; Liver Neoplasms; Solid tumours; Mismatch Repair Deficient Cancer; Carcinoma, Renal Cell; Neoplasms; Skin Neoplasms; Mesothelioma; Colorectal Neoplasms; Melanoma; Neoplasm Metastasis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message